Foghorn Therapeutics Inc (FHTX)
5.35
+0.11
(+2.10%)
USD |
NASDAQ |
Jun 21, 16:00
5.345
0.00 (0.00%)
Pre-Market: 20:00
Foghorn Therapeutics Net Income (Quarterly): -25.02M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -25.02M |
December 31, 2023 | -24.11M |
September 30, 2023 | -14.34M |
June 30, 2023 | -29.49M |
March 31, 2023 | -30.49M |
December 31, 2022 | -28.89M |
September 30, 2022 | -25.77M |
June 30, 2022 | -27.31M |
March 31, 2022 | -26.91M |
December 31, 2021 | -29.14M |
Date | Value |
---|---|
September 30, 2021 | -26.08M |
June 30, 2021 | -23.11M |
March 31, 2021 | -22.99M |
December 31, 2020 | -20.76M |
September 30, 2020 | -18.37M |
June 30, 2020 | -15.72M |
March 31, 2020 | -13.95M |
December 31, 2019 | -15.29M |
September 30, 2019 | -13.09M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-30.49M
Minimum
Mar 2023
-13.09M
Maximum
Sep 2019
-22.68M
Average
-24.11M
Median
Dec 2023
Net Income (Quarterly) Benchmarks
Viridian Therapeutics Inc | -48.54M |
CEL-SCI Corp | -7.245M |
AIM ImmunoTech Inc | -5.817M |
IGC Pharma Inc | -5.589M |
NovaBay Pharmaceuticals Inc | -3.214M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 5.05M |
Total Expenses (Quarterly) | 33.24M |
EPS Diluted (Quarterly) | -0.59 |
Enterprise Value | 21.17M |
Profit Margin (Quarterly) | -495.4% |
Earnings Yield | -41.12% |
Normalized Earnings Yield | -41.12 |